Triple threat: new drug combo aims to tackle Hard-to-Treat prostate cancer
NCT ID NCT07717099
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This phase II pilot trial is testing a three-drug combination—radium-223, darolutamide, and standard hormone therapy—in men with high-volume metastatic hormone-sensitive prostate cancer. The goal is to see if adding radium-223 as maintenance therapy after initial treatment can improve how well patients stick with the regimen and potentially control the disease. The study enrolls about 50 participants and measures treatment completion and PSA response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of radium-223, darolutamide, and androgen deprivation therapy (ADT)
- What this could lead to
- If successful, this approach could improve treatment compliance and outcomes for men with high-volume metastatic prostate cancer.
- What could go wrong
- This is a small, early-phase pilot trial without a control group, so results may not be definitive. The combination may cause side effects or not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Complejo Hospitalario Universitario Materno-Infantil de Gran Canaria (CHUIMI)
Las Palmas de Gran Canaria, 35016, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Complejo Hospitalario Universitario de Santiago (CHUS)
Santiago de Compostela, 15706, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Clínico San Carlos
Madrid, 28040, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Clínico Universitario de Valladolid (HCUV)
Valladolid, 47003, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Santa Creu i Sant Pau
Barcelona, 08041, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitario Central de Asturias (HUCA)
Oviedo, 33011, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitario La Paz
Madrid, 28046, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitario Marqués de Valdecilla
Santander, 39008, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto Valenciano de Oncología (IVO)
Valencia, 46009, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.